# Edenlux

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edenlux

- Industry: Healthcare Specialists
- Headquarters: Busan, South Korea
- Website: www.otuseye.com
- Total disclosed funding: $14M
- Latest round: Series B (Mar 2, 2022)
- Investors on record: 6

## About

Based in South Korea, Edenlux specializes in developing innovative optical health products aimed at enhancing eye wellness and reducing visual fatigue for users.Founded in 2016, Edenlux operates from Busan, South Korea, focusing on optical health products. The company has engaged in 9 deals, with its latest Series B funding round raising KRW 2 billion on December 6, 2023, from Korea Technology Finance Corporation. The company's founders include Andy Bluhm, Christopher Hull, and Pete Helfers, and it is led by CEO Deepak Karandikar.Edenlux specializes in eye health products, focusing on the OTUS Plus, an eye exercise device designed to alleviate visual fatigue and promote ocular wellness. This product is supported by over a decade of research, targeting common vision impairment and eye strain issues. The OTUS Plus allows users to integrate eye relaxation exercises into their daily routines, especially beneficial for individuals with prolonged screen exposure, such as office workers and students. Their customer base primarily consists of health-conscious consumers and professionals in South Korea and expanding international markets.Edenlux generates revenue through direct-to-consumer sales of the OTUS Plus. Customers can purchase the device directly from their online platform, and the transaction model is based on one-time purchases. The company enhances customer engagement through support on platforms like KakaoTalk, contributing to a sustainable revenue stream and brand loyalty among users. Their commitment to eye health positions them as a provider catering to a growing demand for eye care solutions.Edenlux plans to utilize its recent Series B funding of KRW 2 billion raised in December 2023 to support the development of new products and expansion into targeted international markets. The company is designing additional eye health solutions, with specific release dates yet to be announced. They aim to broaden their reach beyond South Korea to include markets across Asia and North America within the next few years.

## Funding rounds

- Series B, Mar 2, 2022, $4.1M — Timeworks Investment, A-Stone Ventures
- Series B, Jan 4, 2022, $4.2M — Korea Development Bank, Korea Investment Partners
- Series A, Jan 13, 2021, $4.3M — Korea Investment & Securities, HB Investment
- Series A, Oct 19, 2017, $1.3M — Korea Investment Partners

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series A
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Timeworks Investment (https://capitalatlas.ai/funds/timeworks-investment) — Series B
- A-Stone Ventures (https://capitalatlas.ai/funds/a-stone-ventures) — Series B